AI-powered
podcast player
Listen to all your favourite podcasts with AI-powered features
3min chapter
Episode 20. Management of Myeloma in LMICs
Blood Cancer Talks
The Barriers to Using Lenalidomide in the Hospital Setting
With limited treatment, we do have randomized trials prior to the rough novel agents showing that transplant versus no transplant, there was clearly an overall survival benefit. So I think that still probably applies if there is limited treatment. Deratumumab as you alluded to is very expensive and many people may not be able to afford that. Definitely the results from these trials cannot be extrapolated to the LMIC setting.
00:00
Transcript
Episode notes
Get the Snipd
podcast app
Unlock the knowledge in podcasts with the podcast player of the future.
AI-powered
Discover
highlights
Listen to the best highlights from the podcasts you love and dive into the full episode
Save any
moment
Hear something you like? Tap your headphones to save it with AI-generated key takeaways
Share
& Export
Send highlights to Twitter, WhatsApp or export them to Notion, Readwise & more
AI-powered
podcast player
Listen to all your favourite podcasts with AI-powered features
Discover
highlights
Listen to the best highlights from the podcasts you love and dive into the full episode